April 6, 2023 03:00 PM EDTUpdated 03:48 PM
Pharma
FDA+

Sam­sung and San­doz ques­tion FDA's 're­search roadmap' for biosim­i­lars de­vel­op­ment

Paul Schloesser

Associate Editor

The FDA last Jan­u­ary asked biosim­i­lar de­vel­op­ers and oth­er stake­hold­ers to com­ment on up­com­ing plans for new biosim­i­lar-re­lat­ed re­search. Over the last two weeks, biosim­i­lar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times